Biliary Strictures Caused by Malignant NeoplasmsNCT07715240
The HANAROSTENT® Multi-Hole™ Biliary Stent is Indicated for Use in the Palliative Treatment of Biliary Strictures Produced by Malignant Neoplasms and the Study is to Demonstrate Clinical Safety and Performance of the Multi-Hole™ Stent for the Palliative Treatment of Malignant Biliary Obstruction.
A study testing Biliary Stent for the Palliative Treatment of Malignant Biliary Obstruction in people with Biliary Strictures Caused by Malignant Neoplasms, run by Olympus Corporation of the Americas.
Trial summary
The objective of this study is to demonstrate clinical safety and performance of the HANAROSTENT® Multi-Hole™ Biliary Stent for the palliative treatment of malignant biliary obstruction. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Biliary Strictures Caused by Malignant Neoplasms
- What is being tested?
- Biliary Stent for the Palliative Treatment of Malignant Biliary Obstruction
- Type of treatment
- Medical device
- How many people
- 66 participants
- Where
- No sites listed yet
- Study dates
- 31 Oct 2026to 30 May 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Suspected or confirmed malignant non-hilar extrahepatic biliary obstruction including any of the following measures of biliary obstruction or patients undergoing neoadjuvant cancer treatment (chemotherapy and/or radiation) for malignant biliary obstruction
- Clinical symptoms including (e.g., cholangitis, jaundice, pruritus, pale stools, and/or dark urine)
- Biochemical evidence (Tbili > 3mg/dL)
- High quality imaging (e.g., ultrasound, CT, MRCP, or ERCP)
- ≥ 18 years of age
- Willing and able to provide informed consent
Who cannot join
- Participation in another investigational study within 90 days prior to consent
- Intrahepatic metastases that extensively involve both lobes of the liver
- Patients with a distal malignant biliary obstruction due to potential resectable disease
- Strictures that could not be traversed by the delivery system
- Perforation of any duct within the biliary tree
- Presence of a biliary self-expanding metal stent (SEMS), esophageal stent, or duodenal stent
Show all 10Show fewer
- Active viral hepatitis
- Life expectancy of < 3 months
- Patient has undergone (within 30 days prior to enrollment) or is planning to undergo brachytherapy with transpapillary or percutaneous implantation of intracavitary radiation sources
- Unwilling or unable to comply with the follow-up schedule
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
Jewel Gill contact
About this study
Official title: Evaluation of the Clinical Safety and Performance of an Investigational Multi-Hole™ Biliary Stent for the Palliative Treatment of Malignant Biliary Obstruction
The objective of this study is to demonstrate clinical safety and performance of the HANAROSTENT® Multi-Hole™ Biliary Stent for the palliative treatment of malignant biliary obstruction.
Read the detailed description
The HANAROSTENT® Multi-Hole™ Biliary Stent is indicated for use in the palliative treatment of biliary strictures produced by malignant neoplasms.
- Being tested
- Biliary Stent for the Palliative Treatment of Malignant Biliary Obstruction
- Keywords
- Biliary Stent, Stent, Biliary Obstruction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Biliary Stent for the Palliative Treatment of Malignant Biliary ObstructionDevice
Multi-hole anti-migration stent for biliary strictures produced by malignant neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary Endpoints
Primary Outcome Measures
- Clinical palliation of biliary obstruction maintenance of total bilirubin (Tbili) at 1-month follow-up < 3 mg/dL OR Tbili reduction by > 30% if the baseline value is > 3 mg/dL and absence of acute cholangitis AND absence of stent-related re-intervention until death, surgery, completion of data collection at 6-month follow-up visit, or withdrawal, whichever occurs first.
Measured: 6 Month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jul 2026
- Study start31 Oct 2026 (estimated)
- Primary completion27 Feb 2027 (estimated)
- Study completion30 May 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Biliary Strictures Caused by Malignant NeoplasmsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 66 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Olympus Corporation of the Americas
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Mayo Clinic, M.I.Tech Co., Ltd.
- Responsible party
- Sponsor
- Investigators
- Ryan J Law, Doctor of Osteopathic Medicine, Principal investigator, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07715240
- Sponsor's protocol ID
- 2025-GI-01
- Status last verified
- Jul 2026
- First submitted
- 6 Jul 2026
- Last updated
- 21 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Clinical Safety and Performance of an Investigational Multi-Hole™ Biliary Stent for the Palliative Treatment of Malignant Biliary Obstruction
- ClinicalTrials.gov ID
- NCT07715240
- Acronym / sponsor ID
- 2025-GI-01
- Keywords
- Biliary Stent, Stent, Biliary Obstruction
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 66 participants (estimated)
- Lead sponsor
- Olympus Corporation of the AmericasIndustry (pharma, biotech, devices)
- Collaborators
- Mayo Clinic, M.I.Tech Co., Ltd.
- Study start
- 31 Oct 2026 (estimated)
- Primary completion
- 27 Feb 2027 (estimated)
- Study completion
- 30 May 2028 (estimated)
- First posted
- 20 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to demonstrate clinical safety and performance of the HANAROSTENT® Multi-Hole™ Biliary Stent for the palliative treatment of malignant biliary obstruction.
Detailed description
The HANAROSTENT® Multi-Hole™ Biliary Stent is indicated for use in the palliative treatment of biliary strictures produced by malignant neoplasms.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- Single blind (participant)
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Suspected or confirmed malignant non-hilar extrahepatic biliary obstruction including any of the following measures of biliary obstruction or patients undergoing neoadjuvant cancer treatment (chemotherapy and/or radiation) for malignant biliary obstruction
- Clinical symptoms including (e.g., cholangitis, jaundice, pruritus, pale stools, and/or dark urine)
- Biochemical evidence (Tbili > 3mg/dL)
- High quality imaging (e.g., ultrasound, CT, MRCP, or ERCP)
- ≥ 18 years of age
Key exclusion criteria (10 listed)
- Participation in another investigational study within 90 days prior to consent
- Intrahepatic metastases that extensively involve both lobes of the liver
- Patients with a distal malignant biliary obstruction due to potential resectable disease
- Strictures that could not be traversed by the delivery system
- Perforation of any duct within the biliary tree
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Biliary Stent for the Palliative Treatment of Malignant Biliary ObstructionMulti-hole anti-migration stent for biliary strictures produced by malignant neoplasms | Device | – |
Primary outcome
Primary Endpoints
Time frame: 6 Month
Primary Outcome Measures 1. Clinical palliation of biliary obstruction maintenance of total bilirubin (Tbili) at 1-month follow-up < 3 mg/dL OR Tbili reduction by > 30% if the baseline value is > 3 mg/dL and absence of acute cholangitis AND absence of stent-related re-intervention until death, surgery, completion of data collection at 6-month follow-up visit, or withdrawal, whichever occurs first.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Biliary Strictures Caused by Malignant Neoplasms
Not yet recruiting
Pre-cut Versus Intentional Double Guidewire for ERCP Cannulation: Prospective, Randomized Controlled Trial
ERCP, Choledocholithiasis
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jewel Gill contact
Ryan J Law, Doctor of Osteopathic Medicine principal investigator
Mayo Clinic
Questions about this trial
What is this clinical trial studying?
A study testing Biliary Stent for the Palliative Treatment of Malignant Biliary Obstruction in people with Biliary Strictures Caused by Malignant Neoplasms, run by Olympus Corporation of the Americas.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 21 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sharon Rabine (484-896-5000, sharon.rabine@olympus.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary Endpoints (time frame: 6 Month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jul 2026.